Observational Study of the Use of KRYSTEXXA (Pegloticase)in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy.

Trial Profile

Observational Study of the Use of KRYSTEXXA (Pegloticase)in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Pegloticase (Primary)
  • Indications Gout
  • Focus Adverse reactions
  • Acronyms EyesOnGOUT
  • Sponsors Horizon Pharma; Savient Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 09 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Jun 2016 Planned End Date changed from 1 Jul 2015 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top